This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Takeda moves to dismiss 'abandoned' US antitrust claims in Amitiza case

( April 7, 2026, 17:07 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceuticals has moved to dismiss "abandoned" statutory monopolization and unfair and deceptive acts and practices claims brought by end payor plaintiffs, who allege the company illegally delayed generic competition to its brand name drug Amitiza. End-payor plaintiffs assert monopolization and UDAP claims under various state statutes, but chose not to propose jury instructions addressing the elements for those claims, "nor have they stated an intention to pursue such claims at trial," Takeda said in a motion-to-dismiss filed in the District of Massachusetts. The claims are abandoned and should be dismissed before trial, the filing said.See attached document:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections